Compare Merck & Co., Inc. (MRK) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Clear Secure Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Clear Secure Inc trades at $57.03 (market cap $5.76B). The key difference: Merck & Co., Inc. is far larger — about 53.3× Clear Secure Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | YOU | |
|---|---|---|
Market Cap | $307.25B | $5.76B |
Sector | Health | Technology |
52-Week High | $129.52 | $62.36 |
52-Week Low | $77.60 | $28.84 |
Enterprise Value | $350.66B | $5.07B |
Dividend Yield | 2.73% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Clear Secure (YOU) trades at $57.18, up 2.05% with a bullish technical outlook. The stock shows strong profitability with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated with a P/E of 45.74. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected. The company continues expanding airport partnerships and launched AWS integration for contact center verification in June 2026.
Growth prospects remain positive with revenue projected to reach $942 million in 2026, but high valuation multiples and mixed analyst ratings (44% Buy, 44% Hold) suggest cautious optimism. Key risks include execution of expansion plans and competitive pressures in identity verification markets. The consensus price target of $56.67 offers limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
